

Daewoong partners with Inventage to expand long-acting injection biz

03 June 2020 | News

The collaboration aims to discover a long-acting injection pipeline, research dosage form, conduct pre-clinical and clinical studies, and build overseas partnerships



Daewoong has announced that the company signed a partnership with Inventage Lab, a drug delivery system platform startup, at its headquarters in Samseong-dong, Seoul, South Korea. With this partnership, both companies collaborate to discover a long-acting injection pipeline, research dosage form, conduct pre-clinical and clinical studies, and build overseas partnerships.

Long-acting injection (LAI) is a novel dosage form that replaces a drug administered orally or by injection daily with an injection once every 1 to 3 months. Its advantage is that it can improve medication adherence, enhance patient convenience, and optimize treatment effects with stable administration.

Daewoong released Luphere Depot Inj, a prostate cancer drug, in the dosage form of LAI and successfully developed it into a KRW 20 billion blockbuster. The company is experienced and capable of the entire process from clinical development, manufacture, marketing authorization, and market release for long-acting injection. Based on its 20 years of LAI production and research, the company has a diverse R&D pipeline for the central nervous system, diabetes and obesity in addition to oncology drugs, and is preparing to advance into the global market by developing its own dual chamber syringe (DCS) and building current Good Manufacturing Practice (cGMP) production facilities.

Inventage Lab has its original IVL-precision particle fabrication method (IVL-PPFM), which suppresses the burst phenomenon where an embedded drug is released rapidly in large quantities. This technology has data with remarkable integrity in release control, which maintains drug blood levels within a certain range while the drug remains active. Inventage Lab is developing various drugs of modified-release dosage form for hair loss, dementia, drug addiction, etc. based on IVL-PPFM, and expanding it as a LAI project for new drugs.

With this partnership, Daewoong is planning to expand its LAI and step up its advances in overseas markets.

Sengho Jeon, CEO of Daewoong, said, "To discover and get ahead with novel LAI items, ensure diversity in platform technology, and take global market opportunities, we decided to sign a strategic partnership with Inventage Lab. Based on both companies' remarkable technology and know-how, we are expecting that we can further enhance our drug discovery competitiveness and expand our pipeline."

Image Caption: *Daewoong CEO Sengho Jeon(right) and Juhee Kim of Inventage Lab are taking photo after the signing agreement*